Adam J. Gadzinski, MD, MS, on Up-and-Coming Research for Urologic Oncology

Video

The expert in urologic oncology spoke about new innovations that he believes will aid in treating patients with urologic cancers.

In an interview with CancerNetwork®,Adam J. Gadzinski, MD, MS, urologic oncology fellow and an acting instructor of Urologic Oncology at the Urology Clinic at UWMC, discussed encouraging research in the field of urologic oncology.

Transcription:

From a new treatment standpoint, some of [the most interesting] areas in prostate, kidney, and bladder cancer [are] the continued immunotherapy developments. Another one that’s very relevant to our world today is continued disparities research. [With] disparities, everyone always initially tends to think of gender and racial disparities; I think inherent into that [are] also very significant socioeconomic and also geographic disparities.

I think there’s going to be new ways of providing urologic care and telemedicine will be one tool for that. I do not think that…telemedicine will fix all disparity access issues for urologic care. I think that that is an over promise for this technology. But I think it can help and it can be used as a tool [for] the person who lives 500 miles away from a referral center [who has] a unique cancer that probably should…at least have treatment guided by that referral center. [This technology] makes it just a lot easier for them to get the input because they don’t have to drive 500 miles or fly that far. They can just have a telemedicine visit from their couch and say, ‘Okay, my local provider can do this, this is great. Thank you so much for your guidance and input,’ and [get] on with their day.

Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content